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Orexin neuropeptides promote arousal, appetite,
reward, and energy expenditure. However, whether
orexin affects bone mass accrual is unknown. Here,
we show that orexin functions centrally through
orexin receptor 2 (OX2R) in the brain to enhance
bone formation. OX2R null mice exhibit low bone
mass owing to elevated circulating leptin, whereas
central administration of an OX2R-selective agonist
augments bone mass. Conversely, orexin also func-
tions peripherally through orexin receptor 1 (OX1R)
in the bone to suppress bone formation. OX1R null
mice exhibit high bone mass owing to a differentia-
tion shift from marrow adipocyte to osteoblast that
results from higher osseous ghrelin expression. The
central action is dominant because bone mass is
reduced in orexin null and OX1R2R double null
mice but enhanced in orexin-overexpressing trans-
genic mice. These findings reveal orexin as a critical
rheostat of skeletal homeostasis that exerts a yin-
yang dual regulation and highlight orexin as a thera-
peutic target for osteoporosis.
INTRODUCTION
Orexin-A and -B (also known as hypocretin-1 and -2) are neuro-
peptides produced in the lateral hypothalamus that stimulate
wakefulness, feeding, thermogenesis, and reward behaviors
(Sakurai, 2007; Sakurai and Mieda, 2011). They function through
two receptors: OX1R and OX2R. Orexin deficiency in human and
mice leads to narcolepsy, hypophagia, and obesity (Chemelli
et al., 1999; Hara et al., 2001; Lin et al., 1999; Peyron et al.,
2000; Sellayah et al., 2011). Hence, there is tremendous pharma-
cological interest in developing orexin-targeting small molecules
for the treatment of sleep and metabolic disorders such asCinsomnia (Brisbare-Roch et al., 2007), obesity, and diabetes
(Funato et al., 2009; Kotz et al., 2012; Sellayah et al., 2011),
some of which has completed Phase III clinical trials.
In vertebrates, the adult skeleton is continuously regenerated
through bone remodeling. This is a dynamic process that tightly
couples osteoblast-mediated bone formation with osteoclast-
mediated bone resorption. Osteoblasts are derived from bone
marrow mesenchymal stem cells (MSCs) that can also differen-
tiate into marrow adipocytes, the balance of which is controlled
by an array of hormones and transcription factors (Bianco et al.,
2013; Wan, 2013). In contrast, osteoclasts are differentiated
from macrophage precursors in response to receptor activator
of NF-kB ligand (RANKL), depending on the ratio of RANKL to
osteoprotegerin (OPG), a RANKL decoy receptor that inhibits
osteoclast differentiation (Novack and Teitelbaum, 2008).
Emerging evidence reveal that neuropeptides, such as neuro-
medin U (NMU) and neuropeptide Y (NPY), modulate skeletal
homeostasis via both central and peripheral functions (Rosen,
2008). However, whether orexin regulates bone mass accrual
is unknown. This is an important question in light of the therapeu-
tic potential of orexin modulators in several diseases. Using both
genetic and pharmacological strategies, we uncover orexin as a
yin-yang dual regulator: on one hand, orexin enhances bone for-
mation via a primary OX2R- and leptin-mediated neuroendocrine
control; on the other hand, orexin also suppresses bone forma-
tion via a secondary OX1R- and ghrelin-mediated local regula-
tion of bone cell differentiation.RESULTS
Orexin Deletion Causes Low Bone Mass and Decreased
Bone Formation
To determine the physiological roles of orexin in skeletal remod-
eling, we examined the orexin knockout mice (OX-KO) (Chemelli
et al., 1999). MicroCT (mCT) analysis of the trabecular bone in the
proximal tibia (Figure 1A) reveals that the OX-KO mice displayed
a low bone mass phenotype. The trabecular bone volume/
tissue volume ratio (BV/TV) was decreased by 38% in OX-KOell Metabolism 19, 927–940, June 3, 2014 ª2014 Elsevier Inc. 927
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Figure 1. Orexin Deletion Causes Low Bone Mass and Decreased Bone Formation
(A–E) mCT analysis of tibiae from OX-KO or WT controls (3 months old, male, n = 9). (A) Images of the trabecular bone of the tibial metaphysis (top) (scale bar
represents 10 mm) and the entire proximal tibia (bottom) (scale bar represents 1 mm). (B–D) Trabecular bone parameters. (B) BV/TV, bone volume/tissue volume
ratio; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation. (C) BMD, bone mineral density. (D) SMI, Structure Model Index.
(E) Additional trabecular and cortical bone parameters. BS, bone surface; BS/BV, bone surface/bone volume; Tb.Porosity, trabecular bone porosity.
(F) Three-point bending assay (n = 9).
(G) Serum P1NP (n = 9).
(H) Serum CTX-1 (n = 9).
(I and J) Static histomorphometry of osteoblast number (Ob.N/B.Ar) (I) and osteoclast number (Oc.N/B.Ar) (J) (n = 9); B.Ar, bone area.
(K–M) Dynamic histomorphometry (3 months old at endpoint, male, n = 5). (K) Images of the trabecular bone at metaphysis and the cortical bone at diaphysis.
Scale bars represent 10 mm. (L) Bone formation rate (BFR/BS). (M) Mineral apposition rate (MAR). Error bars represent SD.
See also Figure S1.
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Orexin Enhances Bone Masscompared to wild-type (WT) controls, accompanied by 22% less
trabecular number (Tb.N), 24% less trabecular thickness (Tb.Th),
36% greater trabecular separation (Tb.Sp) (Figure 1B), and 4%
lower bone mineral density (BMD) (Figure 1C). The Structure
Model Index (SMI), which quantifies the 3D structure for the rela-
tive amount of plates (SMI = 0, strong bone) and rods (SMI = 3,
fragile bone), was 46% higher (Figure 1D). Consistently, OX-
KO mice had lower bone surface (BS), higher BS/BV ratio, and
higher trabecular porosity (Tb.Porosity) (Figure 1E). Moreover,
cortical BV/TV was also decreased, leading to higher cortical928 Cell Metabolism 19, 927–940, June 3, 2014 ª2014 Elsevier Inc.porosity (Figure 1E). Consequently, three-point bending assay
shows that the tibiae of OX-KO mice were weaker as the peak
load at fracture was 13% lower (Figure 1F). Consistent with pre-
vious reports, body weight of OX-KO mice under chow diet was
unaltered (Figure S1A available online).
Serum ELISA shows that the bone formation marker N-termi-
nal propeptide of type I procollagen (P1NP) was 30% lower (Fig-
ure 1G), while the bone resorption marker C-terminal telopeptide
fragments of the type I collagen (CTX-1) was unaltered (Fig-
ure 1H). Static histomorphometry shows that osteoblast number
Cell Metabolism
Orexin Enhances Bone Masswas decreased (Figure 1I), whereas osteoclast number was un-
altered (Figure 1J). Dynamic histomorphometry using double
calcein labeling shows that OX-KO mice exhibited a lower
bone formation rate (BFR/BS) and mineral apposition rate
(MAR) in both trabecular bone at metaphysis and cortical bone
(Figures 1K–1M). These results indicate that orexin augments
bone mass mainly by promoting bone formation.
OX1R but Not OX2R Regulates Mesenchymal Stem Cell
Differentiation
Wenext investigated whether the orexin regulation of bonemass
ismediated by central and/or peripheral actions via OX1R and/or
OX2R. Orexin, OX1R, and OX2R are all expressed in the brain
(Sakurai, 2007), but it was unclear whether they are expressed
in bone. We found that orexin and OX1R, but not OX2R, were ex-
pressed in mouse tibiae (Figures 2A, left, and S1B), indicating a
specific local orexin regulation via OX1R. Tibial orexin expres-
sion, which was absent in OX-KO mice (Figure S1C), originated
from MSCs, osteoblasts and marrow adipocytes but not macro-
phages or osteoclasts (Figures 2A, right, and S1D), suggesting
an autocrine/paracrine regulation in the mesenchymal lineage.
OX1R expression was suppressed during osteoblast differen-
tiation (Figures 2B and 2C) but elevated during adipocyte differ-
entiation (Figures 2D and 2E). Again, OX2R was not expressed in
either culture (Figures 2B and 2D). Marker gene expression
confirmed complete differentiation (Figure S2). This indicates
that OX1R may be proadipogenic and antiosteoblastogenic.
Consistent with this notion, treatment with orexin-A (an agonist
for OX1R and OX2R), but not orexin-B (an agonist for mainly
OX2R), inhibited osteoblast differentiation (Figures 2F and S3A)
and enhanced adipocyte differentiation (Figures 2G and S3B).
Moreover, OX1R inhibitor (SB-408124) or OX1R2R dual inhibitor
(ACT-078573) promoted osteoblast differentiation (Figures 2H
and S3C) and attenuated adipocyte differentiation (Figures 2I
and S3D), whereas OX2R inhibitor (compound 1) had no effect
(Figures 2H, 2I, S3C, and S3D). In contrast, these inhibitors
did not alter osteoclast differentiation (Figure 2J), in line with
the absence of OX1R and OX2R expression in osteoclasts. An
anti-OX-A antibody also increased osteoblast differentiation
but decreased adipocyte differentiation (Figures S3E and S3F).
These results indicate that activation of OX1R inhibits osteoblas-
togenesis from MSCs by favoring marrow adipogenesis.
OX1R Deletion Causes High Bone Mass and Increased
Bone Formation
To investigate whether OX1R inhibits bone formation in vivo, we
next analyzed OX1R-KO mice (Mieda et al., 2011). mCT shows
that OX1R-KOmice exhibited a high bone mass phenotype (Fig-
ure 2K). The trabecular bone in OX1R-KO mice had 40% higher
BV/TV, 54% higher Tb.N, 29% higher Tb.Th, and 39% lower
Tb.Sp (Figure 2L), as well as 5% higher BMD (Figure 2M) and
19% lower SMI (Figure 2N). Cortical bone BV/TV, porosity, and
thickness were not significantly altered (Figure 2O). Moreover,
OX1R-KO mice also had stronger bone as the peak load at
fracture was 20% higher (Figure 2P). Serum P1NP was 37%
increased (Figure 2Q, left), whereas serum CTX-1 was 35%
decreased (Figure 2Q, right). Osteoblast number was higher;
whereas marrow adipocyte number and osteoclast number
were lower (Figure 2R). BFR/BS and MAR in the trabecularCbone at metaphysis was increased (Figure S2). Therefore, the
high bone mass in OX1R-KO mice resulted from a combination
of elevated bone formation and reduced bone resorption.
To determine the cellular mechanisms accounting for the
higher bone formation in OX1R-KO mice, we next compared
bone cell differentiation. Osteoblast differentiation from the
marrow MSCs of OX1R-KO mice was enhanced compared to
WT control mice, shown by the increased number of alkaline
phosphatase+ (ALP+) cells, alizarin red+ cells and von Kossa+
cells (Figure 2T) and the higher expression of osteoblast markers
including runx2, osterix, ALP, osteocalcin, and col1a1 (Fig-
ure 2U). In contrast, adipocyte differentiation was suppressed,
shown by the decreased number of oil-red-o+ (ORO+) cells (Fig-
ure 2V) and the lower expression of adipocyte markers including
PPARg2, adiponectin and FABP4 (Figure 2W). These results are
consistent with the findings in Figures 2B–2I, demonstrating that
OX1R is antiosteoblastogenic but proadipogenic.
Because bone resorption was also decreased in OX1R-KO
mice, we next compared osteoclastogenesis. When stimulated
with the same concentration of RANKL, the bone marrow of
OX1R-KO mice differentiated into osteoclasts to a similar extent
as WT mice (Figure 2X), consistent with the results in Figure 2J.
This indicates that the reduced bone resorption was caused by a
non-cell-autonomous effect. We found that RANKL expression
was lower (Figure 2Y), whereas OPG expression was higher (Fig-
ure 2Z) in OX1R-KO osteoblast differentiation cultures compared
to WT cultures, indicating that the reduced bone resorption
in OX1R-KO mice was mediated by a decreased RANKL/OPG
ratio.
Together, these findings unexpectedly present a dichotomy
where OX1R-KOmice exhibit a high bone mass that is the oppo-
site of the low bone mass in the OX-KO mice, indicating that
additional mechanismsmay dominate over OX1R in orexin regu-
lation of bone. Although OX2R is not expressed in bone, a pos-
sibility exists that OX2R may mediate a central regulation by
orexin. Thus, we next investigated the consequences of OX2R
deletion.
OX2R Deletion Causes Low Bone Mass and Decreased
Bone Formation
mCT shows that OX2R-KO mice (Willie et al., 2003) exhibited a
low bone mass (Figures 3A–3E) as in the OX-KO mice, leading
to a reduced peak load at fracture (Figure 3F). P1NP and osteo-
blast number were decreased, whereas CTX-1 and osteoclast
number were unaltered (Figures 3G–3I). Consistently, BFR/BS
and MAR were reduced in both males (Figure 3J) and females
(Figure S4). In agreement with the lack of OX2R expression
in bone, osteoblast and adipocyte (Figures 2A, 2B, and 2D),
marrow MSCs from OX2R-KO mice displayed normal capacity
to differentiate into osteoblasts (Figure 3K) and adipocytes
(Figure 3L). These results show that OX2R deletion causes low
bone mass that recapitulates the bone defects in OX-KO mice,
due to a reduction in bone formation via potentially a central
mechanism.
Central Administration of an OX2R-Selective Agonist
Augments Bone Mass
To further test the hypothesis that OX2R acts centrally to regu-
late skeletal homeostasis, we performed intracerebroventricularell Metabolism 19, 927–940, June 3, 2014 ª2014 Elsevier Inc. 929
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Orexin Enhances Bone Mass(i.c.v.) injection. An OX2R selective agonist (OX2R-AG) (Ala11,
D-Leu15) orexin-B (Asahi et al., 2003) was continuously infused
in the lateral ventricles of WT mice at 0.5 nmol/day for 35 days
as described (Funato et al., 2009). mCT shows that OX2R-AG
remarkably enhanced bone mass (Figure 3M), leading to 66%
higher BV/TV, 32% higher Tb.N, 30% higher Tb.Th and 33%
lower Tb.Sp (Figure 3N); as well as 8% higher BMD (Figure 3O)
and 25% lower SMI (Figure 3P). The cortical bone had 1% higher
BV/TV and 30% less porosity (Figure 3Q). Moreover, OX2R-AG
also increased bone strength as the peak load at fracture was
11% higher (Figure 3R). P1NP was 100% increased (Figure 3S),
whereas CTX-1 was unaltered (Figure 3T). These results suggest
that central activation of OX2R enhances bone formation and
augments bone mass.
We next investigated whether OX2R-AG i.c.v. injection can
serve as a therapeutic strategy to treat postmenopausal osteo-
porosis in an ovariectomy (OVX) mouse model. Three days
after surgery, we began the i.c.v. infusion at 0.5 nmol/day for
35 days. Uterine weight was reduced by 87% in all ovariecto-
mized mice compared to sham controls, indicating effective es-
trogen depletion (Figure 3U). OVX-mediated reduction in P1NP
was significantly abolished by OX2R-AG (Figure 3V); whereas
OVX-mediated increase in CTX-1 was not significantly altered
(Figure 3W). Moreover, OVX-mediated reduction in osteoblast
number and bone formation rate was also rescued by OX2R-
AG (Figure 3X). Consequently, OVX-induced bone loss was
attenuated in OX2R-AG-treated mice (Figures 3X–3Z). This
bone anabolic effect of OX2R-AG was abolished in OX2R-KO
mice (Figure S5), confirming that it is OX2R dependent. These
results suggest that central activation of OX2R may be a
strategy to ameliorate bone degenerative diseases such as
osteoporosis.
Central Action Is Dominant over Peripheral Action in
Orexin Regulation of Bone
The observation that OX-KO mice exhibited a similar bone
phenotype as OX2R-KO mice rather than OX1R-KO mice sug-Figure 2. OX1R Decreases Bone Mass via a Local Regulation of Bone
(A) Left: expression of orexin, OX1R, and OX2R in mouse tibiae (bone + marrow) (
MSC, mesenchymal stem cell; Ob, osteoblast; Ad, marrow adipocyte; mf, macro
(B) Expression of OX1R and OX2R in marrow osteoblast differentiation cultures (
(C) Expression of OX1R during a time course of osteoblast differentiation (n = 3);
(D) Expression of OX1R and OX2R in marrow adipocyte differentiation cultures (
(E) Expression of OX1R during a time course of adipocyte differentiation (n = 3).
(F and G) Effects of OX-A or OX-B (10 nM) on osteoblast (F) and adipocyte (G) d
(H–J) Effects of OX1R inhibitor (OX1R-I), OX2R inhibitor (OX2R-I), or OX1R2R du
differentiation from WT marrow (n = 3).
(K–O) mCT analysis of tibiae fromOX1R-KO orWT controls (3 months old, male, n =
(P) Three-point bending assay (n = 9).
(Q) Serum P1NP (left) and CTX-1 (right) (n = 9).
(R) Static histomorphometry (n = 9).
(S) Dynamic histomorphometry of the trabecular bone at metaphysis (3 months
(T and U) Osteoblast differentiation from the bonemarrow of OX1R-KO orWT con
Kossa (bottom) stained osteoblast differentiation cultures. (U) Expression of oste
(V and W) Adipocyte differentiation from the bone marrow of OX1R-KO or WT co
Scale bar represents 100 mm. (W) Expression of adipocyte markers (n = 3).
(X) Osteoclast differentiation quantified by TRAP expression (n = 3).
(Y and Z) Expression of RANKL (Y) and OPG (Z) in the osteoblast differentiation cu
and ‘‘n.s.’’ in (U) and (W–Z) compares OX1R-KO with WT control under the same
See also Figures S1–S3.
Cgests that the OX2R-mediated central control is dominant over
the OX1R-mediated peripheral regulation. To further test this
hypothesis, we analyzed the OX1R2R double knockout mice
(1R2R-DKO). mCT shows that 1R2R-DKO mice also exhibited a
low bone mass (Figures 4A–4F). P1NP was decreased whereas
CTX-1 was unaltered (Figures 4G and 4H). Osteoblast number,
BFR/BS, and MAR were reduced whereas osteoclast number
was unaltered (Figures 4I and 4J). OX1R2R double heterozygous
mice did not exhibit any significant bone phenotype (Figure S6).
These results indicate that simultaneous deletion of both OX1R
and OX2R presents an OX2R null phenotype.
As a complimentary gain-of-function approach, we examined
the effects of global orexin overexpression by analyzing the
CAG/orexin-transgenic mice (OX-Tg) (Mieda et al., 2004). The
pattern of orexin overexpression in the OX-Tg mice has been
described (Funato et al., 2009; Mieda et al., 2004): ectopic
orexin immunoreactivity was detected in several CNS regions
as well as in a limited set of peripheral tissues, including thyroid
gland, adrenal cortex, and some pancreatic islets, but not in
other metabolic tissues such as brown and white adipose, liver,
or skeletal muscle. In agreement, the percentage of brown
adipose tissue weight in body weight was unaltered in OX-Tg
mice (0.306% ± 0.017%) compared with WT littermate controls
(0.302% ± 0.019%). Tibial orexin expression was elevated by
115% in the OX-Tg mice compared with controls (Figure S1B).
mCT shows that OX-Tg mice exhibited high bone mass (Figures
4K–4P). Bone formation was elevated as P1NP was 83% higher
(Figure 4Q). Interestingly, chronic global orexin overexpression
also suppressed bone resorption as CTX-1 was 31% lower
(Figure 4R). Osteoblast number, BFR/BS and MAR were higher,
adipocyte number was lower, and osteoclast number was not
significantly altered (Figures 4S and 4T). Together, the results
that bone mass is reduced in OX-KO and 1R2R-DKO
mice but enhanced in OX-Tg mice strongly supports the
notion that the OX2R-mediated central regulation is dominant
over the OX1R-mediated peripheral modulation of bone cell
differentiation.Cell Differentiation
n = 3); n.d., not detected. Right: orexin expression in various cell types (n = 10).
phage; Oc, osteoclast.
n = 3). ObDiff, osteoblast differentiation cocktail.
d, day.
n = 3). AdDiff, adipocyte differentiation medium.
ifferentiation from WT marrow (n = 3).
al inhibitor (1R2R-I) (10 nM) on osteoblast (H), adipocyte (I), and osteoclast (J)
9). (K) Representative images. (L–O) Trabecular and cortical bone parameters.
old, male, n = 5).
trol mice (n = 3). (T) Alkaline phosphatase (ALP, top), alizarin red (middle), or von
oblast markers (n = 3).
ntrol mice (n = 3). (V) Oil red O (ORO) stained adipocyte differentiation culture.
lture (n = 3). ‘‘+’’ and ‘‘n.s.’’ in (F–I) compares treatment with vehicle control; ‘‘+’’
treatment conditions. Error bars represent SD.
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Cell Metabolism
Orexin Enhances Bone MassOX1R Inhibits Osteoblastogenesis by Suppressing Local
Ghrelin Expression
We next set out to elucidate the molecular mechanisms underly-
ing the local and central bone regulation by orexin. We found that
the expression of ghrelin protein was markedly upregulated
in the tibiae of OX1R-KO and 1R2R-DKO mice (Figure 5A). In
contrast, the level of serum ghrelin protein, which largely derives
from the stomach, was unaltered (Figure 5B). This suggests that
OX1R regulation of ghrelin expression occurs locally in the bone.
Indeed, ghrelin mRNA was also higher in the tibiae of OX1R-KO
and 1R2R-DKO mice (Figure 5C).
Ghrelin expression was induced during osteoblast differentia-
tion, which was enhanced in the culture from OX1R-KO mice
compared toWT controls (Figure 5D). In contrast, ghrelin expres-
sion was reduced during adipocyte differentiation, which was
also elevated in the culture from OX1R-KO mice compared to
WT controls (Figure 5E). In line with these findings, the ghrelin in-
duction during osteoblast differentiation was abolished by OX-A
treatment but potentiated by OX1R inhibitor or OX1R2R dual in-
hibitor (Figure 5F). Ghrelin expression in adipocyte differentiation
cultures was also inhibited by OX-A, but enhanced by OX1R in-
hibitor or OX1R2R dual inhibitor (Figure 5G). Furthermore, ghrelin
secretion was elevated by OX1R inhibitor or OX1R2R dual inhib-
itor in both osteoblast (Figure 5H) and adipocyte (not shown)
cultures. Previous studies have shown that ghrelin promotes os-
teoblastogenesis (Delhanty et al., 2006; Fukushima et al., 2005;
Kimet al., 2005;Maccarinelli et al., 2005). Thus, these results indi-
cate that OX1R inhibition of osteoblast differentiation may be
mediated by the suppression of local ghrelin expression in bone.
To further investigate whether ghrelin upregulation was
required for the pro-osteoblastogenic and antiadipogenic effects
of OX1R deletion, we performed ghrelin small interfering RNA
(siRNA) knockdown experiments. Marrow MSCs from WT or
OX1R-KO mice were transfected with ghrelin siRNA (si-Ghrl) or
control siRNA (si-Ctrl) before differentiation. Ghrelin knockdown
in WT cells decreased osteoblast differentiation (Figures S7A–
S7C), supporting the pro-osteoblastogenic role of ghrelin.
Importantly, ghrelin knockdown in OX1R-KO cells to a level
similar to WT cells (Figures 5I and S7D) abolished their ability
to increase osteoblastogenesis, decrease adipogenesis, or alter
RANKL and OPG expression (Figures 5J–5M). These findings
indicate that osseous ghrelin is an essential mediator of the local
bone regulation by OX1R.Figure 3. OX2R Increases Bone Mass via a Central Regulation
(A–E) mCT of tibiae from OX2R-KO or WT controls (3 months old, male, n = 9). (A
(F) Three-point bending assay (n = 9).
(G) Serum P1NP (n = 9).
(H) Serum CTX-1 (n = 9).
(I) Static histomorphometry (n = 9).
(J) Dynamic histomorphometry of the trabecular bone at metaphysis and the cor
(K and L) Osteoblast differentiation (K) and adipocyte differentiation (L) from the
(M–T) Effects of i.c.v. injection of an OX2R agonist (OX2R-AG) on bone in 12-we
images. (N–Q) Trabecular and cortical bone parameters. (R) Three-point bending
(U–Z) Effects of i.c.v. injection of an OX2R-AG on OVX-induced bone loss in 6-mo
CTX-1. (X and Y) mCT and histomorphometry. (X) Top: mCT images; bottom: hist
‘‘Sham+Veh’’; ‘‘+’’ compares ‘‘OVX+OX2R-AG’’ with ‘‘OVX+Veh.’’ (Y) Trabecular b
OX2R-KO with WT control under the same treatment conditions. (U–Z) Statis
comparisons. Error bars represent SD.
See also Figures S4 and S5.
COX2R Augments Bone Formation by Suppressing Serum
Leptin Level
Leptin suppressesbone formation, andserum leptin level is a crit-
ical determinant of bonemass.We found that leptin protein levels
in both bone and serumwere elevated in OX-KO, OX2R-KO, and
OX1R2R-DKOmice but reduced in OX-Tgmice (Figures 6A–6C).
Leptin mRNA showed a similar pattern in white adipose tissue
(WAT) (Figure 6D) butwas undetectable in bone (not shown), indi-
cating that the changes in leptin protein in bonemainly originated
fromperipheral fat via circulation. Consistent with the genetic ev-
idence, i.c.v. injection of an OX2R agonist also decreased serum
leptin in WT mice (Figure 6E). These results indicate that orexin
may enhance bone formation by suppressing leptin levels.
Leptin has been shown to decrease trabecular bone mass at
least in part by activating the sympathetic nerves (Ducy et al.,
2000; Elefteriou et al., 2004). Interestingly, recent studies suggest
that leptin paradoxically increases cortical bone mass at least in
part bydownregulatinghypothalamicexpressionofNPY,aneuro-
peptide that causes bone loss (Baldock et al., 2002; Lee andHer-
zog, 2009; Wong et al., 2013). Because both trabecular and
cortical bone mass was decreased in OX-KO and OX2R-KO
mice but increased in OX-Tgmice, we next examined the sympa-
thetic outflow and hypothalamic NPY expression in these mice.
Expression analyses of UCP1, PGC1a andDio2 in brown adipose
tissue (BAT) show that the sympathetic tone was increased in
OX2R-KO mice but decreased in OX-Tg mice (Figure 6F). In
contrast, expression of NPY in hypothalamus was unaltered (Fig-
ure 6G). These results suggest that orexin augments bone mass
mainly by suppressing leptin activationof the sympathetic nerves.
To further elucidate whether leptin is required for OX2R regu-
lation of bone formation, we performed i.c.v. injection of OX2R-
AG in ob/ob mice that lack functional leptin protein (Zhang et al.,
1994) (Figure 6E). In contrast to WT mice (Figures 3M–3T), the
bone enhancing effects of OX2R-AG was completely abolished
in ob/ob mice, as OX2R-AG was no longer able to increase
BV/TV, Tb.N, Tb.Sp, or P1NP (Figures 6H–6L). These results indi-
cate that leptin is a critical mediator of the central bone regulation
by OX2R.
DISCUSSION
This study has identified orexin as a critical yet previously un-
recognized regulator of bone mass accrual that functions via a) Representative images. (B–E) Trabecular and cortical bone parameters.
tical bone at diaphysis (3 months old, male, n = 5).
marrow of OX2R-KO mice and WT controls (n = 3).
ek-old WT male mice (n = 5). (M–Q) mCT analysis of tibiae. (M) Representative
assay. (S) Serum P1NP. (T) Serum CTX-1.
nth-old WT female mice (n = 4). (U) Uterine weight. (V) Serum P1NP. (W) Serum
omorphometry analyses. p < 0.05 by ANOVA; ‘‘*’’ compares ‘‘OVX+Veh’’ with
one parameters. (Z) Three-point bending assay. ‘‘n.s.’’ in (K) and (L) compares
tical analysis was performed by ANOVA and the post hoc Tukey pairwise
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Figure 4. Central Action Is Dominant over Peripheral Action in Orexin Regulation of Bone
(A–J) Analysis of 1R2R-DKOmice andWT controls (3 months old, male, n = 9). (A–E) mCT of tibiae. (A) Representative images. (B–E) Trabecular and cortical bone
parameters. (F) Three-point bending assay. (G) Serum P1NP. (H) Serum CTX-1. (I) Static histomorphometry. (J) Dynamic histomorphometry (3 months old,
male, n = 5).
(K–T) Analysis of OX-Tg mice (n = 10) and WT littermate controls (n = 8) (3–4 months old, male). (K–O) mCT of tibiae. (K) Representative images. (L–O) Trabecular
and cortical bone parameters. (P) Three-point bending assay. (Q) Serum P1NP. (R) Serum CTX-1. (S) Static histomorphometry. (T) Dynamic histomorphometry
(3 months old, male, n = 5). Error bars represent SD.
See also Figure S6.
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Orexin Enhances Bone Massyin-yang dual mechanism (Figure 6M). On one hand, orexin acti-
vation of OX2R in the brain centrally enhances bone formation by
lowing circulating leptin level. On the other hand, orexin activa-
tion of OX1R in the bone locally suppresses bone formation
and enhances bone resorption by lowering osseous ghrelin
expression. Importantly, the central action is dominant over local
action so that systemic orexin overexpression increases bone934 Cell Metabolism 19, 927–940, June 3, 2014 ª2014 Elsevier Inc.mass whereas complete deletion of orexin or orexin receptors
decreases bone mass. It is remarkable how orexin achieves
a physiological balance in the regulation of skeletal homeosta-
sis by differentially utilizing two different receptors at distinct
anatomic sites.
Orexin deficiency in humans causes behavior abnormalities
including sleep and mood disorders. Both OX-KO and OX2R-KO
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Figure 5. OX1R Inhibits Osteoblastogenesis by Suppressing Local Ghrelin Expression
(A and B) Ghrelin protein levels in tibiae (A) and serum (B) of WT or mutant mice (n = 2).
(C) Ghrelin mRNA levels in tibiae of WT or mutant mice (n = 3).
(D and E) Ghrelin mRNA in osteoblast (D) and adipocyte (E) differentiation cultures from the marrow of OX1R-KO or WT mice (n = 3).
(F–H) Effect of OX-A, OX-B, OX1R-I, OX2R-I, or 1R2R-I (10 nM) on ghrelin expression in marrow differentiation cultures. (F and G) Ghrelin mRNA in osteoblast (F)
and adipocyte (G) cultures (n = 3). (H) Ghrelin protein expression and secretion in osteoblast culture (n = 2).
(I–M) Ghrelin knockdown abolished the enhanced osteoblastogenesis, reduced adipogenesis, and altered RANKL/OPG expression in OX1R-KO differentiation
cultures (n = 3). Marrow MSCs were transfected with ghrelin-siRNA (si-Ghrl) or control siRNA (si-Ctrl) (n = 3). The results are shown as mRNA expression of
ghrelin (I), osteoblast markers (J), adipocyte markers (K), RANKL (L), and OPG (M). ‘‘+’’ and ‘‘n.s.’’ in (D) and (E) compares OX1R-KO with WT control under the
(legend continued on next page)
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Orexin Enhances Bone Massmice exhibit a narcolepsy phenotype, which is characterized
by daytime sleepiness that is accompanied by a sudden loss of
muscle tone known as cataplexy, often after laughter or excite-
ment (Chemelli et al., 1999; Lin et al., 1999). Orexin is undetect-
able in most human narcolepsy patients (Nishino et al., 2000).
Interestingly, older women with sleep disorders are reported to
suffer from greater risk of osteoporotic fractures (Stone et al.,
2006). Moreover, orexin deficiency and sleep disorders are also
frequently associated with major mood disorders (MMD), espe-
cially depression (Allard et al., 2004; Brundin et al., 2007). In hu-
mans, orexin-A levels in amygdala are maximal during positive
emotion butminimal duringdepression, suggesting that boosting
orexin function could elevate mood (Blouin et al., 2013). In mice,
orexin neurons are also maximally active during performance of
rewarded behaviors; OX-KOmice are deficient in conducting re-
warded behaviors; andOX2R-KOmice display increased behav-
ioral despair, indicating a similar involvement of orexin in positive
reinforcement (Borgland et al., 2009;McGregor et al., 2011; Scott
et al., 2011). In humans, depression is associated with low bone
mass and increased incidenceof osteoporotic fractures (Baband
Yirmiya, 2010). A study using a mouse stress model shows that
depression induces bone loss by inhibiting bone formation via
the stimulation of the sympathetic nervous system (Yirmiya
et al., 2006). However, the neural circuitry underlying the connec-
tion of narcolepsy, depression, and bone loss is not well under-
stood. Our findings that OX-KO andOX2R-KOmice exhibit lower
bone mass and higher leptin levels provide a potential mecha-
nism for the increased fracture risk in narcolepsy and depression.
Orexin deficiency is also associated with metabolic abnormal-
ities including obesity and hypophagia (Sakurai, 2007; Sakurai
and Mieda, 2011). The obese phenotype in young mice occurs
only under high-fat diet feeding, but not under chow diet feeding
(Funato et al., 2009; Sellayah et al., 2011), and at least in part due
to decreased energy expenditure and impaired development of
BAT (Sellayah et al., 2011), which have recently been reported
to promote bone formation (Rahman et al., 2013). Interestingly,
the decreased energy expenditure in OX-KO mice was caused
by an OX1R-dependent direct BAT differentiation defect rather
than defects in sympathetic nervous system (Sellayah et al.,
2011). Thus, even if leptin and sympathetic tone are increased
in OX-KO mice due to a central effect, leading to decreased
bone mass, energy expenditure is still lower due to the lack of
BAT. Consistent with this notion, our results show that leptin
levels are only elevated in OX2R-KO, but not OX1R-KO
mice, and reduced by i.c.v. delivery of OX2R-agonist (Figures
6A–6E), indicating that orexin suppresses leptin via a central
regulation. Of note, we found that orexin and orexin receptors
can regulate bone remodeling in the absence of body weight
change under chow diet (Figure S1A). In addition, orexin expres-
sion in the brain (Mieda et al., 2011; Willie et al., 2003) and tibiae
(Figure S1B) are unaltered in the receptor knockout mice.
Furthermore, our previous study shows that OX-Tg mice have
no ectopic orexin protein expression in BAT and WAT (Funatosame culture conditions; ‘‘+’’ and ‘‘n.s.’’ in (F) and (G) compares treatment with
with si-Ctrl in OX1R-KO cells, ‘‘+’’ and ‘‘n.s.’’ compares OX1R-KO cells transfe
represent SD.
See also Figure S7.
936 Cell Metabolism 19, 927–940, June 3, 2014 ª2014 Elsevier Inc.et al., 2009), suggesting that orexin regulation of bone can be in-
dependent from its regulation of BAT. Nonetheless, it is possible
that these other metabolic and behavior changes may indirectly
contribute to the skeletal phenotype observed in orexin and
orexin receptor knockout mice.
Global knockout mice have the advantage of revealing the
net effects of loss-of-function, including both cell-autonomous
and systemic/non-cell-autonomous effects. Indeed, our findings
uncover OX1R in the osteoblasts and OX2R in the brain as two
potential mechanisms contributing to the peripheral and central
bone regulation by orexin, respectively.We have identified a cell-
autonomous role of orexin andOX1R in osteoblast differentiation
and thus provided a key mechanism for how OX1R regulates
bone. It is possible that other non-cell-autonomous effects
may also contribute to the bone phenotype of OX1R-KO mice.
Although i.c.v. injection delivers OX2R agonist to several CNS
regions, it is known that endogenous orexin peptides are also
widely projected in the brain (Sakurai, 2007; Sakurai and Mieda,
2011). The finding that the bone anabolic effects of OX2R agonist
is abolished in the ob/ob mice indicates that leptin may be
an essential mediator of the central bone regulation by orexin
and OX2R; although other indirect mechanisms in ob/ob mice,
such as the altered metabolism, may also contribute to their
resistance to OX2R agonist. Future studies to generate and
characterize conditional knockout mice for orexin and orexin
receptors using flox mice and cre drivers specific for MSCs, pre-
osteoblasts, mature osteoblasts, and specific CNS regions will
further delineate the functional requirement of each tissue and
cell type.
Our in vivo genetic studies usingOX1R knockoutmice, in com-
bination with our in vitro bone marrow osteoblast differentiation
assays using orexin peptides and orexin receptor inhibitors,
demonstrate that OX1R suppresses osteoblast differentiation
and bone formation. Orexin regulation of osteoblastogenesis
has also been implicated in a previous study using rat calvarial
osteoblast-like cells (Ziolkowska et al., 2008). We found that
OX1R inhibits osteoblast differentiation by specifically reducing
osseous ghrelin expression without altering circulating ghrelin
levels (Figure 5), suggesting that distinct mechanisms may ac-
count for the regulation of ghrelin expression in bone and stom-
ach. Our ghrelin siRNA knockdown experiments (Figure 5) and
previous pharmacological experiments (Delhanty et al., 2006;
Fukushima et al., 2005; Kim et al., 2005; Maccarinelli et al.,
2005) show that ghrelin promotes osteoblastogenesis. More-
over, pharmacological studies also show that ghrelin stimulates
growth and appetite. Interestingly however, it is reported that
ghrelin knockout mice are normal with unaltered body weight,
food intake and bone density (Sun et al., 2003). A possible expla-
nation is that developmental compensation in the knockout mice
may mask the physiological role of ghrelin.
The elucidation of the intricate mechanisms underlying orexin
regulation of bone also presents exciting opportunities for the
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Figure 6. OX2R Augments Bone Formation by Suppressing Serum Leptin Level
(A–C) Leptin protein levels in tibiae (A) and serum (B and C), quantified by western blot (A and B) (n = 2) and ELISA (C) (n = 5).
(D) Leptin mRNA in WAT (n = 3). Asterisk in (C) and (D) compares mutant mice with WT controls.
(E) Serum leptin levels were decreased by i.c.v. injection of OX2R-AG in WT mice (n = 5) but not in ob/ob mice (n = 4).
(F) Expression of UCP1, PGC1a, and Dio2 in BAT (n = 5).
(G) NPY expression in hypothalamus (n = 5). Asterisk and n.s. in (F) and (G) compares mutant mice with WT control mice.
(H–L) The bone enhancing effects of OX2R-AG via i.c.v. injection was abolished in ob/ob mice (12 weeks old, male, n = 4). (H–K) mCT of tibiae. (H) Images of the
trabecular bone of the tibial metaphysis (scale bar represents 10 mm). (I–K) Trabecular bone parameters. (L) Serum P1NP. Error bars represent SD.
(M) A simplified working model for how orexin regulates skeletal homeostasis via a yin-yang dual mechanism. On one hand, orexin activation of OX2R in the brain
centrally enhances bonemass via a dominant neuroendocrine mechanism by decreasing circulating leptin levels, thus ameliorating the bone-suppressive effects
of leptin. On the other hand, orexin activation of OX1R in the bone peripherally reduces bone mass via a subordinate autocrine/paracrine mechanism by
decreasing local ghrelin expression, thus compromising the bone-augmenting effects of ghrelin. Consequently, OX1R deletion causes bone gain whereas OX2R
deletion causes bone loss; global orexin deletion leads to bone loss whereas global orexin overexpression leads to bone gain.
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Orexin Enhances Bone MassFirst, OX2R-specific agonists hold tremendous potential as bone
anabolic therapeutics. Second, OX1R-specific antagonists may
present anabolic and anticatabolic dual benefits to enhance
bone formation and suppress bone resorption. Interestingly,
OX2R activation also confers resistance to obesity and diabetesC(Funato et al., 2009; Kotz et al., 2012), hence OX2R agonists
may promote metabolic and skeletal fitness simultaneously.
This prospect is even more exciting in light of the bone loss
side effects observed in the current drugs or drug candidates
for obesity/diabetes such as rosiglitazone (Bilezikian et al.,ell Metabolism 19, 927–940, June 3, 2014 ª2014 Elsevier Inc. 937
Cell Metabolism
Orexin Enhances Bone Mass2013; Grey, 2009; Home et al., 2009; Kahn et al., 2006, 2008;
Zinman et al., 2010) and fibroblast growth factor 21 (FGF21)
(Wan, 2013; Wei et al., 2012).
Several pharmaceutical companies including Merck and
GlaxoSmithKline have developed small molecule orexin antago-
nists for the treatment of insomnia. These include OX1R antago-
nists, OX2R antagonists, and OX1R2R dual antagonists such as
almorexant (ACT-078573) (Brisbare-Roch et al., 2007) and su-
vorexant (MK-4305) (Cox et al., 2010; Willyard, 2012). Suvorex-
ant is under FDA review after completion of Phase III clinical trials
(Mieda and Sakurai, 2013; Willyard, 2012). Our findings suggest
that OX1R-specific antagonist may be bone protective whereas
OX2R antagonists and OX1R2R dual antagonists may risk bone
loss.
More fundamentally, the finding of orexin as a key regulator
of skeletal homeostasis provides insight to our understanding
of how bone remodeling is controlled by neuronal and endo-
crine mechanisms. It also raises a provocative question of how
skeletal physiology may crosstalk with sleep/wake, fast/feeding,
energy store/expenditure cycles, as well as reward, addiction,
anxiety, and motivation behaviors, via the common orexin
pathway in vertebrates.
EXPERIMENTAL PROCEDURES
Mice
OX-KOmice (Chemelli et al., 1999), OX1R-KOmice (Mieda et al., 2011), OX2R-
KOmice (Willie et al., 2003), OX-Tgmice (Mieda et al., 2004), and littermateWT
controls that were backcrossed to the C57BL/6J background for more than
ten generations have been previously described. WT and ob/ob mice on a
C57BL/6J background in the i.c.v. experiments were purchased from Jackson
Laboratory. Mice were fed standard chow containing 4% fat ad libitum. All pro-
tocols for mouse experiments were approved by the Institutional Animal Care
and Use Committee of University of Texas Southwestern Medical Center.
Reagent
OX1R inhibitor (SB-408124) (Langmead et al., 2004) was from Sigma. OX2R
inhibitor (compound 1) (Aissaoui et al., 2008) and OX1R2R dual inhibitor
(ACT-078573, almorexant) (Brisbare-Roch et al., 2007) were synthesized in
the Yanagisawa laboratory. Human orexin-A, orexin-B, and (Ala11, D-Leu15)
Orexin-B (OX2R-specific agonist) peptides were from American Peptide.
Anti-OXR1 (C-19) and anti-leptin (A-20) antibodies were from Santa Cruz
Biotechnology. Anti-Ghrelin (clone 1ML-1D7) and anti-orexin-A were from
Millipore. Ghrelin siRNA and negative control siRNA were from Sigma.
Bone Analyses
mCT and histomorphometry were performed as described (Wei et al., 2010,
2012). Calcein (20 mg/kg) were injected 2 and 10 days before bone collection.
For strength measurement, tibiae were tested by three-point bending, and a
strength parameter (peak load at failure) was assessed with a Test Resources
DDL200 axial loadingmachine outfitted with an Interface SMT1-22 force trans-
ducer. Cross-head displacement rate was 0.1mm/s. Tests were conducted on
the mid-diaphyses with the bones resting on two supports 5 mm apart and the
tibial anterior margins facing upward toward the actuator. Serum P1NP and
CTX-1 were measured with the Rat/Mouse P1NP EIA kit and the RatLaps
EIA kit, respectively (Immunodiagnostic Systems) (Wei et al., 2012).
Ex Vivo Bone Marrow Differentiation
Bone marrow cells were cultured for 4 days in MSC media (Mouse MesenCult
Proliferation Kit, StemCell Technologies), then differentiated into osteoblast
with a-MEM containing 10% FBS, 5 mM b-glycerophosphate, and 100 mg/ml
ascorbic acid for 9 days, or differentiated into adipocytes with adipogenesis
medium (MesenCult Basal Medium + Mouse MesenCult Adipogenic Stimula-
tory Supplement, StemCell Technologies) for 7 days (Wei et al., 2011a,938 Cell Metabolism 19, 927–940, June 3, 2014 ª2014 Elsevier Inc.2011b, 2012). For ghrelin knockdown, siRNA was transfected twice with
FuGENEHD (Roche) the day before and 3 days after differentiation. Osteoclast
differentiation was performed as described (Wan et al., 2007; Wei et al., 2010).
Chronic i.c.v. Injection
Mice were single-housed 1 week before surgery. After anesthetizing with 2%–
3% isoflurane, a cannula (3300PM/SPC; PlasticsOne) was implanted into the
right lateral ventricle (0.3 mm posterior from the bregma, 0.9 mm lateral from
themidline, and 2.4mm from the surface of skull) using standard sterile stereo-
tactic techniques as described (Funato et al., 2009). An osmotic minipump
(model 1004; Alzet) was attached to the cannula and implanted in the subcu-
taneous space. The OX2R selective agonist ([Ala11, D-Leu15] Orexin-B;
American Peptide) (Asahi et al., 2003) or PBS control was continuously
injected in the lateral ventricle for 35 days (0.5 nmol/day) before analyses.
Ovariectomy or sham operation was performed 3 days before i.c.v. infusion
as described (Wei et al., 2011b).
Statistical Analyses
All statistical analyses were performed with Student’s t test and represented
as mean ± SD unless stated otherwise. The p values were designated as:
*p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001; n.s. nonsignificant (p > 0.05).
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